UPDATE: Alcobra Issues Protocol to FDA for Phase IIb Study of Metadoxine ER for Treatment of Fragile X Syndrome

Alcobra Ltd. (Nasdaq: ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its ...